Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma


Adult Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Previously Untreated Childhood Rhabdomyosarcoma | Stage IV Adult Soft Tissue Sarcoma

What is the purpose of this trial?

This randomized pilot clinical trial is studying the side effects and how well giving
temozolomide and cixutumumab together with combination chemotherapy works in treating
patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as cixutumumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Giving
temozolomide and cixutumumab together with combination chemotherapy may kill more tumor

Participation Guidelines

N/A - 49 Years

Click here for detailed information about who can participate in this trial.

National Cancer Institute (NCI)
January 2010
Last Updated:
November 20, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01055314